Furthermore, in animal models, the administration of fenofibrate or aminoimidazole-4-carboxamide riboside (AICAR), activators of PPAR-α and AMPK, respectively, improved hepatic insulin resistance [52,53]. The gene discussed is PPARA; the disease is Insulin resistance.